| Title: |
Standardization of Terminology, Definitions, and Outcome Criteria for Bleeding in Hereditary Hemorrhagic Telangiectasia: International Consensus Report. |
| Authors: |
Al-Samkari, Hanny; Kasthuri, Raj S; Mager, Hans-Jurgen; Zhou, Jenny Y; Serra, Marcelo M; Samuelson-Bannow, Bethany T; Van Doren, Layla N; Piccirillo, Jay F; Clancy, Marianne S; McCrae, Keith R; Thomas, Sonia M; Riera-Mestre, Antoni; Pishko, Allyson M; Sewaralthahab, Sarah; Gossage, James R; Iyer, Vivek N; Hermans, Cédric; Hammill, Adrienne; Winship, Ingrid; Mei-Zahav, Meir; von Drygalski, Annette; Olitsky, Scott; Faughnan, Marie E |
| Contributors: |
UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire; UCL - (SLuc) Service d'hématologie |
| Source: |
American journal of hematology, Vol. 100, no.10, p. 1813-1827 (2025) |
| Publisher Information: |
Wiley-Blackwell |
| Publication Year: |
2025 |
| Collection: |
DIAL@USL-B (Université Saint-Louis, Bruxelles) |
| Subject Terms: |
Humans; Telangiectasia; Hereditary Hemorrhagic; Terminology as Topic; Hemorrhage; Consensus; Severity of Illness Index; HHT; Hereditary hemorrhagic telangiectasia; Osler‐Weber‐Rendu; anemia; angiogenesis; bleeding; epistaxis; gastrointestinal bleeding; iron deficiency |
| Description: |
Hereditary hemorrhagic telangiectasia (HHT, Osler-Weber-Rendu disease) is the second most common inherited bleeding disorder worldwide, affecting approximately 1 in 5000 people. Development of disease-modifying and efficacious hemostatic agents to treat HHT has finally begun after decades without such medical therapies. However, the lack of consensus on standardized severity definitions, outcome criteria, and terminology remains a major obstacle to clinical investigation and therapeutic development in HHT. Additionally, with the ongoing repurposing of antiangiogenic agents and emerging development of novel HHT-specific therapies, comparative clinical trials are expected in the future. Therefore, to end the problematic heterogeneity hindering these efforts, the Global Research and Medical Advisory Board (GRMAB) of the Cure HHT Foundation, an international group of recognized HHT experts, convened a conference of expert HHT clinician-investigators from within GRMAB as well as invited external experts in HHT and bleeding disorders generally, patients with HHT, and patient advocates to define standard terminology and definitions for outcomes and severity classification for bleeding and anemia in HHT. These criteria and definitions should be adopted by regulators, investigators, and the pharmaceutical industry in the development and performance of interventional clinical trials and cohort studies to allow improved comparability between clinical trials, facilitate communication between clinicians and investigators, improve therapeutic guideline development, and provide a standardized framework for regulatory agencies. SEARCH STRATEGY AND SELECTION CRITERIA: Evidence for this report was systematically identified and evaluated utilizing two search strategies in Ovid MEDLINE, described in full detail in the Appendix, pp.4-13. The searches were conducted on January 7, 2025. The titles and abstracts of each record were reviewed, and the inclusion criteria were applied to all search results to identify full text articles to ... |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
boreal:310802; https://hdl.handle.net/2078.1/310802; info:pmid/40662351 |
| DOI: |
10.1002/ajh.70011 |
| Availability: |
https://hdl.handle.net/2078.1/310802; https://doi.org/10.1002/ajh.70011 |
| Rights: |
info:eu-repo/semantics/openAccess |
| Accession Number: |
edsbas.591DA09F |
| Database: |
BASE |